Intranasal oxytocin improves symptom severity in patients with major depressive disorder (MDD) lacking BPD, but has no effect on patients with comorbid BPD, revealing that its action varies based on patient characteristics [94]. The gene discussed is OXT; the disease is major depressive disorder.